Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 15/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 14/20 | 0.48 |
| ▸ | OPRK1 | P41145 | 5/20 | 0.48 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | MLNR | O43193 | 1/20 | 0.41 |
| ▸ | RARB | P10826 | 1/20 | 0.41 |
| ▸ | PLK1 | P53350 | 1/20 | 0.41 |
| ▸ | THRA | P10827 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8314826 | 0.83 | OPRD1 (0.50) | OPRD1OPRM1OPRK1ABCB11KCNH2 | |
| SCHEMBL21384863 | 0.75 | OPRD1 (0.61) | OPRD1OPRM1OPRK1ABCB11KCNH2 | |
| SCHEMBL168272 | 0.74 | CA2 (0.56) | KCNH2RARBPLK1THRATHRB | |
| P-Xylene SCHEMBL9064447 | 0.74 | CA2 (0.56) | KCNH2RARBPLK1THRATHRB | |
| SCHEMBL365821 | 0.72 | CA2 (0.54) | KCNH2RARBPLK1THRATHRB | |
| Ammonia Solution, Strong SCHEMBL9428103 | 0.72 | CA2 (0.54) | KCNH2RARBPLK1THRATHRB | |
| SCHEMBL12620502 | 0.69 | HAO1 (0.60) | RARBPLK1THRATHRB | |
| SCHEMBL4125045 | 0.69 | ALDH1A1 (0.51) | RARBPLK1THRATHRB | |
| SCHEMBL6545940 | 0.69 | CA2 (0.50) | KCNH2RARBPLK1 | |
| SCHEMBL2492800 | 0.69 | RARB (0.58) | RARB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200392125-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2020-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200392125-A1 | HETEROCYCLIC COMPOUNDS | LPXN, MLX, CCNY | OPRD1 1395/4885OPRM1 549/4885OPRK1 1592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.